Adaptimmune Ther ADR (ADAP)
0.2653 -0.0013 (-0.49%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime 0.2755 +0.0102 (-) 04/25/25
for Fri, Apr 25th, 2025
Try Excel 
Watch
-
Add or delete the symbol from one or more Watchlists.
-
Create New Watchlist
This name already in use.
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -70,814 | -113,871 | -165,456 | -158,090 | -130,092 |
| Depreciation Amortization | 11,225 | 9,840 | 6,075 | 6,567 | 7,594 |
| Accounts receivable | 29,765 | -1,291 | -9,813 | -19,358 | 1,747 |
| Accounts payable and accrued liabilities | 9,619 | -9,087 | 4,408 | 4,207 | 3,867 |
| Other Working Capital | -36,979 | -24,952 | -1,531 | 134,634 | 56,045 |
| Other Operating Activity | -16,022 | -1,519 | 24,548 | 42,769 | 7,248 |
| Operating Cash Flow | $-73,206 | $-140,880 | $-141,769 | $10,729 | $-53,591 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -56,361 | 135,030 | 118,877 | 84,581 | -276,018 |
| PPE Investments | -886 | -4,681 | -29,496 | -8,574 | -2,341 |
| Net Acquisitions | N/A | 45,264 | N/A | N/A | N/A |
| Purchase Sale Intangibles | -1,834 | -199 | -244 | -207 | -565 |
| Other Investing Activity | -1,705 | 925 | -244 | -207 | -565 |
| Investing Cash Flow | $-58,952 | $176,538 | $89,137 | $75,800 | $-278,924 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 49,500 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 29,249 | 880 | 12,867 | 3,288 | 340,051 |
| Financing Cash Flow | $78,749 | $880 | $12,867 | $3,288 | $340,051 |
| Exchange Rate Effect | -402 | 877 | -2,299 | 365 | -960 |
| Beginning Cash Position | 147,017 | 109,602 | 151,666 | 61,484 | 54,908 |
| End Cash Position | 93,206 | 147,017 | 109,602 | 151,666 | 61,484 |
| Net Cash Flow | $-53,811 | $37,415 | $-42,064 | $90,182 | $6,576 |
| Free Cash Flow | |||||
| Operating Cash Flow | -73,206 | -140,880 | -141,769 | 10,729 | -53,591 |
| Capital Expenditure | -886 | -4,681 | -29,496 | -8,574 | -2,341 |
| Free Cash Flow | -74,092 | -145,561 | -171,265 | 2,155 | -55,932 |